Skip to main content
SpringerLink
Log in

Effects of carvedilol on renal function

  • Pharmacology and Hemodynamics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

A randomized, double-blind, placebo-controlled study was conducted to study the effects of acute and chronic administration of carvedilol in essential hypertension, with special emphasis on renal haemodynamics and function. Acute administration of a single dose of 50 mg carvedilol reduced systolic and diastolic blood pressure without inducing reflex tachycardia. Renal blood flow was preserved; accordingly, renal vascular resistance was significantly reduced. A significant reduction in the glomerular filtration rate and filtration fraction was observed. Plasma renin activity (PRA) and plasma aldosterone values were not changed. Chronic carvedilol treatment produced a significant fall in systolic and diastolic blood pressure, heart rate, PRA and plasma aldosterone. Renal blood flow, glomerular filtration rate and filtration fraction also remained unchanged; renal vascular resistance decreased significantly. It is concluded that carvedilol possesses definite antihypertensive and renal vasodilating properties, both acutely and after chronic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Freis ED (1960) Hemodynamics in hypertension. Physiol Rev 40: 27–54

    Google Scholar 

  2. Zacest R, Reece PA (1984) Hydralazine. In: Doyle AD (ed) Clinical pharmacology of antihypertensive drugs. (Handbook of hypertension, vol 5) Elsevier, Amsterdam, pp 312–349

    Google Scholar 

  3. Zacest R (1976) The vasodilator-β-blocker interaction — some determinants of its clinical success. Aust N Z J Med 6 [Suppl 3]: 65–76

    Google Scholar 

  4. Hansson L (1983) Drug treatment of hypertension. In: Robertson JIS (ed) Clinical aspects of essential hypertension. Handbook of hypertension, vol 1 Elsevier, Amsterdam, pp 397–436

    Google Scholar 

  5. Eggertsen R, Hansson L (1985) Vasodilators in hypertension — a review with special emphasis on the combined use of vasodilators and β-adrenoceptor blockers. Int J Clin Pharmacol Ther Toxicol 23: 411–423

    PubMed  Google Scholar 

  6. Gilmore E, Weil J, Chidsey C (1970) Treatment of essential hypertension with a new vasodilator in combination with β-adrenergic blockade. N Engl J Med 282: 522–527

    Google Scholar 

  7. Gottlieb TB, Katz FH, Chidsey CA (1972) Combined therapy with vasodilator drugs and β-adrenergic blockade in hypertension. Circulation 45: 571–582

    PubMed  Google Scholar 

  8. Zacest R, Gilmore E, Koch-Weser J (1972) Treatment of essential hypertension with combined vasodilation and β-adrenergic blockade. N Engl J Med 286: 617–622

    PubMed  Google Scholar 

  9. Hansson L, Zweiffler AJ (1973) Combined treatment of hypertension with vasodilatation and β-adrenergic blockade. Mich Med 72: 695–698

    PubMed  Google Scholar 

  10. Abshagen U (1987) A new molecule with vasodilating and β-adrenoceptor blocking properties. J Cardiovasc Pharmacol 10 [Suppl 11]: S23-S32

    Google Scholar 

  11. Strein K, Sponer G, Müller-Beckmann G, Bartsch W (1987) Pharmacological profile of carvedilol, a compound with β-blocking and vasodilating properties. J Cardiovasc Pharmacol 10 [Suppl 11]: S33–841

    Google Scholar 

  12. Tomlinson B, Bompart F, Graham BR, Liu JB, Prichard BNC (1988) Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Drugs 36 [Suppl 6]: 37–47

    Google Scholar 

  13. Gragnon JA, Mailloux LV, Doulittle JE, Teschan PE (1970) An isotopic method for instantaneous measurements of effective renal blood flow. Am J Physiol 218: 180–186

    PubMed  Google Scholar 

  14. Blaufox MD (1989) Measurement of renal function with radioactive materials. In: Blaufox MD (ed) Evaluation of renal function and disease with radionuclides: the upper urinary tract. Karger, Basel, pp 12–27

    Google Scholar 

  15. Meyer-Sabellek WA, Schulte KL, Thiede HM, Gotzen R (1983) Acute hypotensive response to the new antihypertensive agent BM 14.190 in essential hypertensive patients. J Hypertens 1 [Suppl 2]: 351–352

    PubMed  Google Scholar 

  16. Eggertsen R, Andren L, Sivertsson R, Hansson L (1984) Acute hemodynamic effects of carvedilol (BM 13190), a new combined β-adrenceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol 27: 19–22

    PubMed  Google Scholar 

  17. Eggertsen R, Sivertsson R, Andren L, Hansson L (1984) Haemodynamic effect of carvedilol, a new β-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens 2: 529–534

    PubMed  Google Scholar 

  18. Hansson L, Zweiffler AJ, Julius S, Hunyor SN (1974) Hemodynamic effect of acute and prolonged β-adrenergic blockade in essential hypertension. Acta Med Scand 196: 27–34

    PubMed  Google Scholar 

  19. Prichard NC, Owens CWI (1980) β-Adrenoceptor blocking drugs. In: Doyle AE (ed) Clinical pharmacology of antihypertensive drugs. Elsevier, Amsterdam, pp 169–224

    Google Scholar 

  20. Weber MA, Drayer JIM (1980) Renal effects of β-adrenoceptor blockade. Kidney Int 18: 686–699

    PubMed  Google Scholar 

  21. Epstein M, Oster JR (1982) β-Blockers and the kidney. Miner Electrolyte Metab 8: 237–254

    PubMed  Google Scholar 

  22. Epstein M, Oster JR (1985) β-Blockers and renal function: a reappraisal. J Clin Hypertens 1: 65–99

    Google Scholar 

  23. Dupont AG, Van der Niepen P, Bossuyt AM, Jonckheer MH, Six RO (1985) Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function. Br J Clin Pharmacol 20: 93–99

    PubMed  Google Scholar 

  24. Piepsz A, Ham HR, Dupont AG (1989) Renal blood flow in renal disease and hypertension. In: Blaufox MD (ed) Evaluation of renal function and disease with radionuclides: the upper urinary tract. Karger, Basel, pp 150–194

    Google Scholar 

  25. Rasmussen S, Nulsen PE (1981) Blood pressure, body fluid volumes, and glomerular filtration rate during treatment with labetalol in essential hypertension. Br J Clin Pharmacol 12: 349–353

    PubMed  Google Scholar 

  26. Cruz F, O'Neill WM, Clifton G, Wallin JD (1981) Effects of labetalol and methyldopa on renal function. Clin Pharmacol Ther 30: 57–63

    PubMed  Google Scholar 

  27. Ljungman S, Aurell M, Hartford M, Wickstrand J, Wilhemsen L, Berglund G (1980) Blood pressure and renal function. Acta Med Scand 108: 17–25

    Google Scholar 

  28. Hollenberg NK, Adams DF (1976) The renal circulation in hypertension disease. Am J Med 60: 773–784

    PubMed  Google Scholar 

  29. De Leeuw PW, Schalekamp MADH, Birkenhäger WH (1983) The renal circulation in hypertension. In: Robertson JIS (ed) Clinical aspects of essential hypertension. (Handbook of hypertension, vol 1) Elsevier, Amsterdam, pp 202–204

    Google Scholar 

  30. Taylor EM, Roe AM, Slater RA (1979) SKF 92657, a novel antihypertensive acting by precapillary vasodilatation and β-adrenergic blockade. Clin Sci 57: 433S-436S

    PubMed  Google Scholar 

  31. Bockringer K, Weidmann P, Link L, Bianhetti L, Schiffl H, Reubi FC (1983) Acute effects of combined vasodilation and β-adrenoceptor blockade with prizidilol on renal function. Br J Clin Pharmacol 15: 181–188

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Hospital Vrije Universiteit, Laarbeeklaan 101, B-1090, Brussels, Belgium

    A. G. Dupont

Authors
  1. A. G. Dupont
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dupont, A.G. Effects of carvedilol on renal function. Eur J Clin Pharmacol 38 (Suppl 2), S96–S100 (1990). https://doi.org/10.1007/BF01409473

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01409473

Key words

Search

Navigation